Q2/2024 6/30/2024 EPS -0.090 ZacksConsensus -0.370 ActVsEst 0.280 - Beat
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid BiopsyBusiness Wire
- Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $85.00 to $75.00. They now have an "overweight" rating on the stock.MarketBeat
- Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Jefferies Financial Group Inc. from $84.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
- Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a "buy" rating on the stock.MarketBeat
EXAS
Earnings
- 11/5/24 - Miss
EXAS
Sec Filings
- 11/13/24 - Form SC
- 11/13/24 - Form 4
- 11/8/24 - Form SC
- EXAS's page on the SEC website